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Detection of early changes 
in the post‑radiosurgery vestibular 
schwannoma microenvironment 
using multinuclear MRI
Daniel Lewis1,2,3*, Damien J. McHugh4, Ka‑loh Li3, Xiaoping Zhu3, Catherine Mcbain2,5, 
Simon K. Lloyd6,7, Alan Jackson3, Omar N. Pathmanaban1,2,8, Andrew T. King1,2,9 & 
David J. Coope1,2,10
Stereotactic radiosurgery (SRS) is an established, effective therapy against vestibular schwannoma 
(VS). The mechanisms of tumour response are, however, unknown and in this study we sought 
to evaluate changes in the irradiated VS tumour microenvironment through a multinuclear MRI 
approach. Five patients with growing sporadic VS underwent a multi‑timepoint comprehensive MRI 
protocol, which included diffusion tensor imaging (DTI), dynamic contrast‑enhanced (DCE) MRI and 
a spiral 23Na‑MRI acquisition for total sodium concentration (TSC) quantification. Post‑treatment 
voxelwise changes in TSC, DTI metrics and DCE‑MRI derived microvascular biomarkers  (Ktrans,  ve 
and  vp) were evaluated and compared against pre‑treatment values. Changes in tumour TSC and 
microvascular parameters were observable as early as 2 weeks post‑treatment, preceding changes in 
structural imaging. At 6 months post‑treatment there were significant voxelwise increases in tumour 
TSC (p < 0.001) and mean diffusivity (p < 0.001, repeated‑measures ANOVA) with marked decreases in 
tumour microvascular parameters (p < 0.001, repeated‑measures ANOVA). This study presents the first 
in vivo evaluation of alterations in the VS tumour microenvironment following SRS, demonstrating 
that changes in tumour sodium homeostasis and microvascular parameters can be imaged as early as 
2 weeks following treatment. Future studies should seek to investigate these clinically relevant MRI 
metrics as early biomarkers of SRS response.
Sporadic vestibular schwannomas (VS) are benign tumours arising from the Schwann cells lining the vestibu-
locochlear or eighth cranial nerve within the cerebellopontine angle (CPA)1–3. With an incidence of 15–20 per 
million per year, VS account for nearly 8% of all intracranial tumours and although histologically benign they 
can cause considerable morbidity due to both their anatomical location and unpredictable, sometimes rapid 
 growth1,3,4. Traditionally the mainstay of management for growing tumours has been microsurgical resection 
but stereotactic radiosurgery (SRS) is also an effective treatment alternative in selected  patients5–7. SRS offers 
several distinct advantages over surgical resection not least of which is the shorter recovery post-treatment and 
the potentially lower risk of facial nerve  injury6,7. There are nonetheless well recognized challenges in the use 
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of SRS as a therapy in these tumours. Unlike surgery where total or near total macroscopic tumour resection is 
often achieved, SRS does not acutely reduce tumour volume but rather attenuates tumour growth over a variable 
period of many months to  years8,9. The timeline to volume reduction in any given tumour is therefore unpredict-
able and following treatment there is a well recognized 10% of VS that demonstrate continued tumour  growth8,9.
At present, there is no way to predict response to SRS either prior to or immediately following treatment. 
Assessing success or failure of treatment is further complicated by the fact that reactive swelling and radiologi-
cal appearance of tumour enlargement is commonly seen for up to 3 years after irradiation, following which 
shrinkage may be  seen8,9. There is currently no way of determining whether this continued growth is treatment 
failure or reactive  swelling6,9. The inability to differentiate between these two radically different responses to 
treatment means that cases of treatment failure are not recognized until after 3 years of continued growth, with 
the consequent surgical challenges of dealing with what is likely to be a significantly larger tumour with potential 
radiotherapy induced adherence to the adjacent cranial nerves and brain  stem8,10.
Fundamental to these clinical challenges is our incomplete understanding of how and why these tumours 
respond to radiotherapy in the way they  do11,12. Radiotherapy as a treatment preferentially targets rapidly dividing 
cells but studies to date have shown that schwannoma cell proliferation rates in VS are low and poorly associated 
with tumour  growth13–15. Indeed recent research has demonstrated that, within growing tumours, infiltrating 
macrophages rather than neoplastic Schwann cells account for the majority of proliferating  cells1,3,16. To better 
predict and monitor treatment responses in VS following SRS we, therefore, need a greater understanding of 
how the microenvironment in these tumours changes following treatment.
In other tumours treated with SRS such as cerebral metastases, advanced diffusion and perfusion MR imag-
ing techniques have demonstrated utility in monitoring treatment responses. In such studies early reductions 
in tumour cytoarchitecture and reductions in perfusion MRI parameters such as the fractional plasma volume, 
 vp, and the transfer constant,  Ktrans (a hybrid parameter reflecting tissue blood flow, vessel surface area, and 
vessel permeability), have been demonstrated following  therapy17–22. There has been a paucity of such studies 
in VS, however. One advanced MR imaging technique which has received increased attention as a marker of 
treatment response in neuro-oncology is sodium (23Na)  MRI23–25. Quantifying changes in total tissue sodium 
concentration (TSC) provides information on cellular physiology and tumour microstructure not obtainable 
with conventional 1H MRI and 23Na-MRI has been shown to be sensitive to therapy-induced changes in both 
systemic and central nervous system  tumours23–28. The goal of the present study was to therefore use both 23Na-
MRI and a comprehensive 1H-MRI protocol including diffusion MRI and dynamic contrast-enhanced (DCE) 
MRI to evaluate cellular, microstructural and microvascular changes in VS following SRS.
Methods
Patient population and treatment. Between February and June 2019 five patients with sporadic VS 
were recruited via the Skull Base Unit multidisciplinary team (MDT) meeting at our institution. All patients 
had undergone routine MR follow-up as part of their clinical care and all tumours were classified as growing by 
the multidisciplinary team meeting. Between March and June 2019, all five patients underwent single-fraction 
stereotactic radiosurgery (SRS) as the primary treatment modality. All patients were treated with frameless lin-
ear accelerator-based SRS using the Novalis TX and ExacTrac treatment systems (Varian Medical Systems, Palo 
Alto, CA, USA) equipped with 6MV SRS mode, HD120 multi-leaf collimator (MLC). An aquaplast mask was 
used for non-invasive immobilization. For treatment planning patients underwent stereotactic MRI at 1.5 T 
(General Electric Medical Systems, Milwaukee, WI, USA) and MRI images were then fused to high-resolution 
CT obtained at the time of simulation to assist in treatment volume design. Dosimetric planning was performed 
using the Pinnacle planning system and all patients received 12 Gy in a single fraction. Ethical approval was in 
place for the study from the National Research Ethics Service Greater Manchester North-West research ethics 
committee (REC reference: 18/NW/0094) and all patients provided written informed consent for study partici-
pation. All research was performed in accordance with local policies and guidelines and in accordance with the 
Declaration of Helsinki.
MRI acquisition. In addition to standard pre-treatment clinical MR sequences, patients underwent imaging 
with a comprehensive research MRI protocol at the following timepoints: pre-treatment (4 patients), 2 weeks 
post-treatment (5 patients), 8  weeks post-treatment (4 patients) and 6  months post-treatment (4 patients). 
Two patients underwent imaging at four timepoints (pre-SRS, 2 weeks post-treatment, 8 weeks post-treatment, 
and 6 months post-treatment) and three patients were imaged at three timepoint. Details of when each patient 
underwent the research MRI protocol are shown in Table 1. For all patients, MRI data were acquired on a 3 Tesla 
whole-body scanner (Philips Achieva, Philips Medical System, NL). High spatial resolution 3D T1W (T1W) 
gradient-echo images with full brain coverage (TE 3.2 ms, TR 8.6 ms, voxel size 1 × 1 × 1 mm) both before and 
after contrast agent (gadoterate meglumine; Dotarem, Guerbet S.A.) administration was obtained for tumour 
delineation. A focused high-spatial resolution T2W-DRIVE (T2-weighted fast imaging with driven equilibrium 
radiofrequency reset pulse) acquisition through the CPA was also obtained (TE 237 ms, TR 2000 ms, voxel size 
0.23 × 0.23 × 0.5 mm). Diffusion-tensor imaging (DTI) was performed using 15 directions and two b-values (0 
and 800 s/mm2) and acquisition parameters were as follows: TE 74 ms, TR 6056 ms, voxel size 1.75 × 1.75 × 2 mm.
DCE‑MRI protocol. DCE-MRI data were collected at three timepoints (pre-treatment, 2  weeks, and 
6  months post-treatment) using a previously described dual-injection, dual temporal resolution (DTR) 
 technique29. A macrocyclic gadolinium-based contrast agent (GBCA, gadoterate meglumine; Dotarem, Guerbet 
S.A.) was administered by power injector as an intravenous bolus at a rate of 3 ml/s, followed by a chaser of 
20 ml of 0.9% saline administered at the same rate. For the first part of this DTR technique, a high temporal but 
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low spatial resolution sequence with a low dose of GBCA (fixed volume of 3 ml) was performed (LDHT-DCE). 
The LDHT-DCE series used a 3D GRE sequence with a flip angle of 16°, a field-of-view of 240 × 240 mm, image 
matrix of 96 × 96 × 22 voxels, and temporal resolution (Δt) of 1.3 s (n = 300). Subsequently, a full GBCA dose 
(0.1 mmol/kg), high spatial but low temporal resolution (FDHS DCE) acquisition (voxel size of 1 × 1 × 2 mm; 
matrix size of 240 × 240 × 70, Δt = 10.1 s, n = 60) was performed to provide high spatial resolution data. Variable 
flip angle (VFA; α = 2°, 6°, 12° and 16°) acquisitions were performed prior to the LDHT and FDHS DCE series 
for native longitudinal relaxation rate  (R1N) mapping.
23Na‑ MRI protocol. Prior to the above 1H sequences a 23Na-MRI acquisition for TSC estimation was per-
formed using a separate dual tuned 1H/23Na birdcage head coil (RAPID Biomedical, Rimpar, Germany). The 
total acquisition time was approximately ~ 14 min. To allow for quantification of TSC in both tumour and nor-
mal appearing brain, two sodium calibration phantoms made from a stock of 60 mM and 120 mM sodium 
chloride (NaCl) in water with 4% agarose was used and placed beside the ear defenders/headphones worn by the 
subjects to include them in the imaging field-of-view (FOV)23,30. The spiral 23Na-MRI images were reconstructed 
on the scanner and the TSC maps were subsequently calculated offline using MATLAB 2015a (The MathWorks, 
Inc., Natick, MA, USA)31. Further details on the 23Na- MRI protocol and analysis can be found in Supplementary 
methods.
1H‑MRI analysis. DTI data were processed using a standard multistep procedure and the FSL 4.1 Diffusion 
Toolbox (http:// www. fmrib. ox. ac. uk/ fsl/)32,33. After correction for misregistration between successive images 
due to Eddy currents and/or patient movement, brain extraction was undertaken and voxelwise maps of mean 
diffusivity (MD) and fractional anisotropy (FA) were generated using the “DTIFIT” tool within  FSL16,32,33.
Voxelwise maps of the microvascular kinetic parameters  Ktrans, vp and  ve (the fractional volume of extravas-
cular extracellular space) were derived from the DCE-MRI datasets using the extended Tofts model (ETM)22. 
To permit high spatial resolution assessment of changes in tumour microvascular parameters following SRS 
treatment, a previously tissue-validated DCE-MRI analysis technique, termed LEGATOS (LEvel and rescale 
the Gadolinium contrast concentrations curves of high-temporal TO high Spatial DCE-MRI) was  adopted34,35. 
For vascular input function (VIF) estimation the dynamic MRI signal from voxels in the superior sagittal sinus 
(SSS) was  used36. An example VIF used for the DCE-MRI analysis is shown in Supplementary Fig. S1 alongside 
an example fit to a tumour. Further details on the LEGATOS analysis technique and the derivation of the VIF 
for this analysis can be found in supplementary methods and included  reference35.
Image co‑registration and segmentation. Longitudinal co-registration was performed for each par-
ticipant for all scan visits. TSC maps, DCE-MRI microvascular kinetic parameter maps and diffusion parameter 
maps from each visit were co-registered to the pre-treatment dataset using a rigid affine co-registration within 
 SPM1237 (SPM12, UCL, London, UK). In all cases the accuracy of co-registration was visually inspected prior to 
further analyses. To allow accurate comparison of longitudinal changes in imaging parameters (TSC, diffusion 
metrics and DCE-MRI derived microvascular parameters) in each tumour ROI and across each tumour voxel, 
individual tumours were manually delineated on the co-registered pre-treatment T1W post-contrast image 
using Analyze version 11 (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN, USA) to create a tumour 
object mask. These object masks, defined on the pre-treatment T1W post-contrast image for each patient, were 
then applied to the co-registered TSC maps, DCE-MRI microvascular kinetic parameter maps and the diffusion 
parameter maps (MD, FA).
Table 1.  Clinical features, delivered radiation dose and details of when each patient underwent the research 
MRI protocol. a Age at time of SRS treatment.
Patient 1 2 3 4 5
Age 70.2 71.2 69.9 73.7 79.1
Gender F F F M F
Tumour laterality Right Left Right Right Left
Pre-treatment tumour volume  (cm3) 0.85 1.3 1.03 1.59 1.2
Tumour Koos grade III III III III III
Prescription dose (gy) 12 12 12 12 12
Gardner-Robertson (GR) hearing classification II (Serviceable) IV (Poor) I (Good) III (Non-serviceable) II (Serviceable)
Mean dose-gross total volume (cGy) 1467.7 1448.2 1471.1 1467 1434.9
Mean Dose- planned target volume (cGY) 1423.5 1400.5 1436.2 1434.9 1427.1
Pre-treatment
Imaging Y X Y Y Y
2 weeks post-treatment imaging Y Y Y Y Y
8 weeks post-treatment imaging Y Y X Y Y
6 months post-treatment imaging X Y Y Y Y
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To evaluate TSC values in normal appearing brain, tissue masks of white matter (WM), grey matter (GM), 
and cerebrospinal fluid (CSF) were derived through automated segmentation of co-registered 3D T1W images 
(SPM12, UCL, London, UK). To reduce the effect of partial volume, only voxels with a tissue probability larger 
than 95% were included in the segmented GM, WM, and CSF  masks23. To corroborate the TSC values obtained 
through automated segmentation a hand‐drawn region-of-interest (ROI) analysis was performed using Analyze 
version 11. ROIs were drawn within the normal appearing white matter of the centrum semiovale (CS) and within 
the CSF of the lateral ventricles for each patient.
To evaluate the repeatability of DCE-MRI derived microvascular parameters across each timepoint a refer-
ence ROI mask was manually delineated on muscle tissue (masseter/temporalis muscle) within the imaging 
 FOV38–40. This muscle ROI mask was delineated on the co-registered pre-treatment T1W post-contrast image 
using Analyze version 11 (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN, USA) and then applied 
to the co-registered DCE-MRI microvascular kinetic parameter maps so that longitudinal temporal changes in 
muscle microvascular parameters could be assessed.
Tumour volume estimation. For evaluation of tumour volume changes during treatment individual 
tumour volumes at each timepoint were determined through semi-automatic segmentation using the BrainLab 
iPlan software (BrainLAB, Feldkirchen, Germany). In addition to the study MRI scans, volumetric measure-
ments of tumour size were also made for the preceding clinical scan so that the pre-treatment volumetric growth 
rate for each individual VS could be  calculated3,16. Acquired high spatial resolution T2W images (i.e., T2W-
DRIVE) was used for all segmentations and corroborated where available against tumour volumes measured on 
T1W post–contrast sequences. The results of all segmentations were reviewed and where necessary, edited by an 
experienced neuroradiologist.
Statistical analysis. Stata version 11 and the SPSS statistical software package (version 25, IBM Corp.) 
were used for all statistical analyses. The test–retest coefficient of variation (CoV) was used for testing the intra-
subject repeatability of GM, WM, and CSF TSC values across each imaging timepoint and the repeatability of 
DCE-MRI derived microvascular parameters within the reference muscle ROI. For each subject, i, the CoV is 
the SD, σi, for all measurements on that subject, divided by the mean, μi, for the subject. The global test–retest 
CoV for a group of N subjects was defined as 
√
∑
(σ/µ)2/N41,42. The average measures intraclass correlation 
coefficient of TSC values from each atlas (GM, WM, CSF) and ROI defined region (CS, CSF lateral ventricle) was 
also calculated using an absolute-agreement, 2-way mixed-effects  model43.
Voxelwise temporal changes in TSC, diffusion metrics, and DCE-MRI derived microvascular kinetic param-
eters  (Ktrans,  ve and  vp) within each tumour voxel were evaluated using a repeated-measures ANOVA with Green-
house–Geisser correction for non-sphericity. To account for missing timepoint data in three patients, temporal 
changes in voxelwise parameter values, mean whole tumour ROI values and tumour volume values across all 
patients studied were analysed using a repeated-measures mixed-effects model with imaging timepoint as a fixed-
effects  variable44. In both approaches post hoc analysis of pairwise comparisons between different timepoints 
were performed using the Bonferroni method.
The voxelwise relationship between TSC, diffusion metrics and DCE-MRI derived microvascular kinetic 
parameters  (Ktrans,  ve and  vp) at each timepoint was evaluated using scatterplot analysis and reported as Spear-
man’s rho. To evaluate the relationship between longitudinal changes in these metrics and changes in different 
tumoural cellular compartments, the percentage of voxels at each post-treatment timepoint demonstrating an 
increase in either the extracellular sodium population (defined as an increase in both TSC and MD or TSC and 
 ve) or intracellular sodium population (defined as an increase in TSC with a decrease in MD or  ve) relative to 
pre-treatment values was calculated and compared for non-equality using a one-sample test of proportions. 
The percentage of voxels displaying both increased TSC/MD and increased  ve,  Ktrans or  vp was also derived and 
compared across each post-treatment timepoint.
Results
Patient population. Demographic details of the study patients are presented in Table 1. Median age at time 
of treatment was 71.2 years (Range 69.9–79.1 years). Four patients were female. In three patients the VS was 
right-sided. Median time between pre-treatment imaging and SRS was 4 days (range 1–6 days). The median time 
(range) to each post-treatment imaging timepoint was 14 days (13–16 days), 57 days (55–70 days), and 181 days 
(160–184 days) respectively. All tumours were Koos grade  III45. Mean pre-treatment VS size was 1.16 ± 0.27  cm3 
and mean pre-treatment growth rate was 0.59 ± 0.23  cm3/yr (Table 2). Mean tumour volume change at 2 weeks, 
8 weeks and 6 months respectively was 0.01, 0.05, and 0.22  cm3 but these differences were not statistically signifi-
cant (p > 0.05, repeated-measures mixed-effects model, Table 2). At time of clinical follow-up six weeks follow-
ing SRS, hearing loss was reportedly worse in one patient (patient 1) and unchanged in 4 patients; one patient 
(patient 2) reported worsened left-sided facial sensory disturbance following treatment.
Total sodium concentration (TSC) in normal appearing brain. Mean total sodium concentration 
(TSC) in atlas defined GM and WM at each timepoint is shown in Supplementary Table S1. Mean pre-treatment 
TSC in atlas defined GM, WM, and CSF was 39.4 ± 3.11 mM, 35.4 ± 2.27 mM and 69.9 ± 3.39 mM respectively, in 
line with previously reported whole-brain literature  values23,25,46. Use of a manual ROI based analysis displayed 
a comparable mean pre-treatment WM TSC of 35.8 ± 4.03 mM for centrum semiovale and a higher CSF TSC of 
113 ± 4.71 mM within the lateral ventricle, reflecting the reduced partial volume effects on measured CSF TSC 
using this approach (supplementary Table S2).
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Intra-subject variance of TSC values in normal appearing brain across each timepoint was low with mean CoV 
values of 9.0%, 10.2%, and 4.25% for atlas defined GM, WM, and CSF respectively (Supplementary Table S3). 
Intra-observer repeatability across all regions was good (ICC > 0.65) with both atlas-defined and ROI-based 
CSF values demonstrating excellent repeatability (ICC 0.91–0.94). There was no correlation between serum  Na+ 
concentration and TSC values in either normal appearing brain or tumour (Spearman’s rho, p > 0.05).
Sodium bioscales demonstrate early post‑SRS changes in VS. Mean pre-treatment TSC across the 
four VS with available imaging was 50.1 ± 26.6 mM (Supplementary table S4) and was significantly higher than 
WM TSC values (p = 0.02, ANOVA). Changes in total sodium concentration were evident as early as 2 weeks 
post-treatment and preceded changes in both structural imaging and diffusion parameter maps (Fig. 1, Sup-
plementary Fig. S2,S3). As shown in Table 3 across all four tumours with pre-treatment imaging there was a 
significant voxelwise increase in TSC at 2 weeks (p < 0.001) and 6 months (p < 0.001) post-SRS compared to pre-
treatment values (repeated-measures ANOVA).
At 8 weeks there was heterogeneity in tumour response with two tumours demonstrating a significant voxel-
wise increase in TSC (Patient 1 and 4, p < 0.001, Fig. 1) and 1 tumour demonstrating a significant decrease in TSC 
compared to pre-treatment values (patient 5, Supplementary Fig. S2). Whole tumour ROI analysis demonstrated 
that compared to pre-treatment values there were statistically significant increases in both absolute mean tumour 
TSC and the tumour-to-CSF TSC ratio at 6 months post-treatment (p ≤ 0.02, repeated-measures mixed-effects 
model,  Supplementary Table  S4).
Temporal trends in tumour diffusion metrics (MD, FA) at 8 weeks and 6 months post‑treat‑
ment mirror changes in tumour TSC. In the four VS studied there was a significant voxelwise reduction 
in FA at 8 weeks (p < 0.001) and 6 months post-treatment (p < 0.001, repeated-measures mixed-effects model, 
Table 3). In contrast to early (2 week) post-treatment TSC changes there was considerable heterogeneity in MD 
and FA values with tumours displaying an increase (patient 1 and 4, p < 0.001, Fig. 1) or decrease in voxelwise 
MD values compared to pre-treatment values (patient 3, p < 0.001, supplementary Fig. S3). In corroboration of 
the voxelwise changes, whole tumour ROI analysis (Supplementary Table S4) demonstrated that at 6 months 
post-treatment there were significant increases in tumour MD (p < 0.001) and decreases in mean tumour FA 
(p = 0.003, repeated-measures mixed-effects model).
Temporal changes in VS microvascular parameters are visible as early as 2 weeks 
post‑SRS. There was no significant change in the  ve,  Ktrans or  vp values of the reference muscle ROI at any 
timepoint (p > 0.05, repeated measures mixed-effects model, supplementary table S5). The intra-subject variabil-
ity of  ve,  Ktrans and  vp values for muscle across each imaging timepoint was low with mean CoV values of 11.8%, 
23.2% and 27.2% respectively (Supplementary Table S5).
In Table 4 voxelwise temporal changes in tumour DCE-MRI derived microvascular parameters are shown. 
There were significant voxelwise decreases in  ve (p < 0.001),  Ktrans (p < 0.001) and  vp (p < 0.001) at 6 months post-
treatment compared with pre-treatment values (repeated-measures ANOVA). This decrease was clearly visualized 
on acquired parametric maps, occurred predominantly within the CPA portion of the tumour, and was associ-
ated with a reduction in central contrast enhancement on post-contrast T1W imaging (Fig. 2, Supplementary 
Fig. S4,S5). Changes in tumour microvascular parameters at the early 2 week post-treatment timepoint were 
more heterogenous (Fig. 2). Two patients demonstrated increases in  ve,  Ktrans and  vp at 2 weeks post-treatment 
(patient 1 and 3, Fig. 2), one patient demonstrated increases in  ve and  vp only (patient 4, Supplementary Fig. S4) 
and one patient demonstrated significant decreases in all three microvascular parameters at 2 weeks (p < 0.001, 
repeated-measures ANOVA, patient 5, Supplementary Fig. S5). Temporal changes in whole tumour ROI DCE-
MRI derived microvascular parameters are shown in Supplementary Table S6.
Voxelwise correlation between TSC, diffusion metrics and microvascular parameters. With 
the exception of one tumour (patient 2) all VS demonstrated a significant (p ≤ 0.05) positive voxelwise correla-
Table 2.  Temporal changes in VS volume post-treatment. a Repeated measures mixed-effects model with post 
hoc pairwise comparison using the Bonferroni method. Acquired high spatial resolution T2W images (i.e., 
T2W-DRIVE) was used for all volume segmentations across all timepoints.
Patient
Pre-treatment tumour 
growth rate  (cm3/yr.)
Tumour volume,  cm3
Pre 2 weeks 8 weeks 6 mon
1 0.24 0.76 0.72 0.70
2 0.55 1.20 1.22 1.28 1.24
3 0.88 1.07 1.08 1.25
4 0.59 1.51 1.54 1.58 1.79
5 0.71 1.25 1.26 1.26 1.24
Mean ± SD 0.59 (0.23) 1.16 (0.27) 1.17 (0.28) 1.21 (0.37) 1.38 (0.27)
Mean difference from baseline,  cm3 (95% CI) 0.01 (− 0.57, 0.59) 0.05 (− 0.57, 0.66) 0.22 (− 0.39, 0.84)
P  valuea 0.99 0.99 0.99
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Figure 1.  Post-SRS changes in tumour total sodium concentration (TSC) and diffusion metrics (MD, FA). 
(A) Line-graphs demonstrating temporal trend in mean tumour TSC (mM), MD  (mm2  s−1 ×  10−6) and FA (no 
units) for five VS. Average trend (red line) across all tumours also shown. (B) Representative TSC and diffusion 
metric maps from the right-sided growing VS shown in Panel A (patient 4, P4). From left to right: co-registered 
voxelwise maps of TSC, MD, and FA. Note the observable increase in TSC at 2 weeks, 8 weeks and 6 months 
post-SRS compared to pre-treatment values within the tumour (arrow) and the comparatively later visible 
increase in MD and reduction in tumoural FA observable at 6 months post-SRS. (C) Histogram of voxelwise 
TSC values within the tumour shown in panel B (patient 4, P4). From left to right: Pre-treatment, 2 weeks 
post-treatment, 8 weeks post-treatment, and 6 months post-treatment. Note the rightward shift in voxelwise 
TSC values at 2 weeks, 8 weeks, and 6 months post-treatment compared to pre-treatment values. ***p < 0.001 
for comparison with pre-treatment TSC value, repeated-measures ANOVA with post hoc (Bonferroni) analysis 
of pairwise comparisons. Arrows show movement in histogram relative to preceding imaging timepoint. FA 
Fractional anisotropy (no units); MD Mean diffusivity  (mm2  s−1 ×  10−6); TSC Total sodium concentration (mM).
Table 3.  Voxelwise temporal changes in tumour total sodium concentration (TSC), mean diffusivity (MD) 
and fractional anisotropy (FA). Statistically significant values (p ≤ 0.05) are shown in bold P value calculated 
using repeated measures ANOVA or repeated measures mixed-effects model. Post hoc analysis of pairwise 
comparisons between different timepoints was performed using the Bonferroni method. *** ≤ 0.001; ** ≤ 0.01; 
* ≤ 0.05. a Difference from 2 week post-treatment timepoint shown as no pre-treatment imaging dataset.
Patient
Voxelwise Δ TSC (mM)
Mean difference (95% CI)
Voxelwise Δ MD  (mm2  s−1 ×  10–6)
Mean difference (95% CI)
Voxelwise Δ FA
Mean difference (95% CI)
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0.01)
− 0.03 (− 0.04, 
− 0.02)***
− 0.09 (− 0.10, 
− 0.08***
All 8.30 (7.91, 8.67)***
3.03 (2.54, 
3.52)*** 12.6 (12.2, 13.0)***








− 0.01 (− 0.02, 
− 0.007)***
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Table 4.  Voxelwise temporal changes in tumour DCE-MRI derived microvascular parameters. Statistically 
significant values (p ≤ 0.05) are shown in bold P value calculated using repeated measures ANOVA or repeated 
measures mixed-effects model. Post hoc analysis of pairwise comparisons between different timepoints was 
performed using the Bonferroni method. ***≤ 0.001; **≤ 0.01; *≤ 0.05. a Difference between post-treatment 
timepoints shown as no pre-treatment imaging dataset.
Patient
Voxelwise Δve (no units)
Mean difference (95% CI)
Voxelwise Δ  Ktrans  (min−1)
Mean difference (95% CI)
Voxelwise Δ  vp (no units)
Mean difference (95% CI)
Pre/2 weeks Pre/6 months Pre/2 weeks Pre/6 months Pre/2 weeks Pre/6 months
1 0.11 (0.09,0.13)*** 0.04 (0.03, 0.04)*** 0.009 (0.005,0.14)***
2a − 0.02 (− 0.04, 0.002) − 0.06 (− 0.07,− 0.06)*** − 0.02 (− 0.02, − 0.01)***
3 0.004 (− 0.008, 0.16) − 0.20 (− 0.22, − 0.18)*** 0.04 (0.03,0.05)*** − 0.12 (− 0.13, − 0.10)*** 0.02 (0.02, 0.03)*** − 0.03 (− 0.04,− 0.03)***
4 0.01 (0.008,0.02)*** − 0.02 (− 0.03,− 0.005)** − 0.02 (− 0.02, − 0.01)*** − 0.08 (− 0.09,− 0.08)*** 0.004 (0.003, 0.006)*** − 0.03 (− 0.04, − 0.03)***
5 − 0.07 (− 0.09, − 0.06)*** − 0.13 (− 0.16, − 0.11)*** − 0.001 (− 0.004, 0.003) − 0.03 (− 0.03, − 0.02)*** − 0.007 (− 0.01, − 0.005)*** − 0.004 (− 0.007, 0.00)*
All − 0.004 (− 0.01, 0.004) − 0.09 (− 0.10, − 0.08)*** 0.009 (0.005, 0.01)*** − 0.07 (− 0.074,− 0.067)*** 0.008 (0.007, 0.01)*** − 0.02 (− 0.022, − 0.018)***
Figure 2.  Post-SRS changes in tumour microvascular parameters. (A) Line-graphs demonstrating temporal 
trend in mean tumour  ve (no units),  Ktrans  (min−1) and  vp (no units) for five VS. Average trend (red line) across 
all tumours also shown. (B) Representative parameter maps from the right-sided growing VS shown in Panel A 
(patient 3, P3). From left to right: T1W post-contrast, co-registered voxelwise maps of  ve,  Ktrans, and tumour  vp. 
Note the early increase in tumour  Ktrans and  vp at 2 weeks post-treatment (arrow) followed by marked reductions 
in  ve,  Ktrans, and  vp within the cerebellopontine angle portion of the tumour at 6 months post-SRS (*). (C) 
Histogram of voxelwise  Ktrans values within the tumour pre-treatment (top), 2 weeks post-treatment (middle) 
and 6 months post-treatment (bottom). ***p < 0.001 for comparison with pre-treatment TSC values, repeated-
measures ANOVA with post hoc (Bonferroni) analysis of pairwise comparison. Arrows show movement in 
histogram relative to preceding imaging timepoint.
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tion between TSC and mean diffusivity at each timepoint and a negative correlation between TSC and FA (Sup-
plementary Table S7). The correlation between TSC and mean diffusivity values across all tumour voxels was 
higher at 2 weeks (rho = 0.51, p < 0.001), 8 weeks (rho = 0.44, p < 0.001) and 6 months post-treatment (rho = 0.45, 
p < 0.001) compared to pre-treatment values (rho = 0.41, p < 0.001).
Across all tumour voxels there was a weak negative correlation of pre-treatment voxelwise TSC with  ve 
(rho = -0.06, p < 0.001),  Ktrans (rho = -0.04, p < 0.001) and  vp values (rho = -0.27, p < 0.001). At 6 months post-
treatment there was a negative correlation of TSC with both  Ktrans (rho = -0.24, p < 0.001) and  vp (rho = -0.24, 
p < 0.001), with no correlation observed between TSC and  ve (rho = -0.002, p = 0.92). The voxelwise correlation 
between tumour diffusion metrics (MD, FA) and tumour DCE-MRI derived microvascular parameters  (ve, 
 Ktrans and  vp) is shown in Supplementary Table S8. Pre-treatment across all tumour voxels there was an inverse 
correlation between MD and  ve values (rho = -0.38, p < 0.001), and at 6 months post-treatment MD correlated 
inversely with all three microvascular parameters (p < 0.001).
Post‑SRS increases in tumour TSC reflect increases in the extravascular‑extracellular space 
and correspond with regions of reduced tumour vascularity at 6 months post‑treatment. Fig-
ure  3A/B and Supplementary Table  S9 shows the percentage of tumour voxels at each timepoint displaying 
increases in TSC, mean diffusivity and  ve compared to pre-treatment. The percentage of all voxels displaying 
an increase in TSC at 2 weeks, 8 weeks and 6 months following treatment was 80.9%, 61.5%, and 98.5% respec-
tively. At 2 weeks post-treatment 43.1% of all tumour voxels displayed an increase in the extracellular sodium 
population (↑23Na: ↑MD). A significantly lower number of voxels (37.8 vs 43.1%, p < 0.001, one-sample test of 
proportions) demonstrated an increase in the intracellular sodium population (↑23Na: ↓MD). Voxelwise  ve values 
corroborated this with 50.3% and 30.6% of voxels demonstrating an increase in extracellular (↑23Na: ↑ve) and 
intracellular (↑23Na: ↓ve) sodium population respectively (p < 0.001, one-sample test of proportions).
Between 2 and 8 weeks post-treatment, the percentage of voxels demonstrating an increase in TSC relative 
to pre-treatment values decreased, with 34.8% and 26.7% of all voxels demonstrating increases in the extracel-
lular and intracellular sodium population respectively when compared to pre-treatment values. At 6 months 
post-treatment, however, 98.5% of all tumour voxels demonstrated increases in TSC compared to pre-treatment 
with the large majority (83.5% vs 15.0%, p < 0.001, one-sample test of proportions) demonstrating increases in 
extracellular (↑23Na: ↑MD) rather than intracellular (↑23Na: ↓MD) sodium.
As shown in Supplementary Table S10 and Fig. 3C, the percentage of voxels with increased TSC or MD 
displaying increased  Ktrans decreased from ~ 50% at 2 weeks post-treatment to only ~ 16% at 6 months post-
treatment. The  ve and  vp values paralleled these changes with ~ 76% and 83 – 85% of all tumour voxels displaying 
decreases in  ve and  vp respectively at 6 months, despite increases in MD and TSC. In Fig. 3D/E voxelwise scat-
terplots of TSC, mean diffusivity (MD) and  Ktrans are shown for a representative patient (patient 5) and clearly 
demonstrate the increase in the percentage of tumour voxels displaying increased TSC and MD but decreased 
 Ktrans at 6 months post-treatment.
Discussion
This study demonstrates that advanced MRI techniques such as 23Na-MRI and DCE-MRI permit the early 
interrogation of changes in the microstructure, microvasculature, and cellular physiology of VS undergoing 
SRS. In particular we demonstrate that increases in tumour TSC measured through 23Na-MRI, are detectable 
as early as 2 weeks following radiotherapy, preceding changes in macroscopic tumour structure and tumour 
diffusion metrics. Through a concomitant DCE-MRI acquisition we furthermore show that early changes in the 
VS microvasculature can be detected following SRS and that following an early post-treatment rise in tumour 
microvascular parameters such as  Ktrans and  vp in some VS, there is a marked decrease in these parameters at 
6 months following treatment.
TSC has been previously investigated as a biomarker of tumour response to fractionated chemo/radiotherapy 
but to date there have been no studies in histologically benign tumours such as  VS23–25,27,28. Thulborn et al. 
interrogated changes in TSC at the voxel level in patients with high grade glioma undergoing fractionated radio-
therapy, demonstrating that voxelwise TSC values were responsive to radiation effects on a weekly time scale, 
with ‘responsive’ tumour regions displaying an early sharp increase in TSC following  radiotherapy24,25. Huang 
et al. in a 7 T study of a cerebral metastasis undergoing SRS similarly demonstrated a dramatic increase in the 
23Na-MRI signal intensity within the tumour at 48 h post-treatment, an effect the authors postulated was due to 
radiotherapy-induced cellular  apoptosis47.
In the present study we show that following radiotherapy, there is an early rise in VS sodium content 
with > 80% of tumour voxels demonstrating an increase in TSC at 2 weeks post-treatment. Whilst an increase 
in intracellular sodium secondary to radiation induced cellular apoptosis or disrupted cellular membrane ion 
transport may in part underlie this increase, the majority of voxels demonstrating increased TSC also displayed 
concomitant increases in mean  diffusivity28,48, a biomarker thought to predominantly reflect extracellular dif-
fusion. This indicates that the TSC rise observed in the majority of tumour voxels at 2 weeks is likely reflective 
of increases in the extravascular-extracellular space, a finding corroborated by the comparable voxel percentage 
demonstrating an increase in both  ve and TSC at this timepoint. Necrosis of radiosensitive tumour cell popula-
tions could in part explain this early rise in TSC, but the demonstrated rise in the DCE-MRI derived metric  Ktrans 
in some tumours suggest that increases in tumoural vascular permeability and interstitial oedema may also be 
a possible mechanism through which this occurs.
At 2 and 8 weeks post-treatment there was considerable heterogeneity across the VS studied with different 
tumours displaying increases and decreases in TSC and MD respectively., This may be explained by varia-
tions between individual tumours and tumour regions in the extent and timing of varying pathophysiological 
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Figure 3.  Temporal changes in extracellular and intracellular total sodium population and DCE-MRI derived 
microvascular parameters. (A) Bar-chart showing percentage of all tumour voxels demonstrating increased 
TSC and an increase (↑TSC: ↑MD) or decrease in MD (↑TSC:↓MD) at 2 weeks, 8 weeks, and 6 months 
post-treatment. Note the increase in the percentage of tumour voxels displaying ↑TSC: ↑MD at 6 months 
post-treatment. (B) Bar-chart showing percentage of all tumour voxels demonstrating increased TSC and an 
increase (↑TSC: ↑ve) or decrease in  ve (↑TSC:↓ve) at 2 weeks and 6 months post-treatment. Note the increase 
in the percentage of tumour voxels displaying ↑TSC but ↓ve at 6 months post-treatment. P value shown is for 
comparison of all tumour voxels displaying an increase in either the extracellular (↑TSC:↑MD or ↑TSC:↑ve) 
or intracellular (↑TSC:↓MD or ↑TSC:↓ve ) sodium population (one-sample test of proportions **P < 0.01 
***P < 0.001). (C) Bar-chart showing percentage of tumour voxels with increased TSC (↑TSC) that display 
an increase (↑) or decrease (↓) in  Ktrans and  vp at 2 weeks and 6 months post-treatment. Note the increase in 
the percentage of tumour voxels displaying ↓Ktrans and ↓vp at 6 months post-treatment. P value shown is for 
comparison of all tumour voxels displaying either an increase or decrease in  Ktrans and  vp respectively (one-
sample test of proportions **P < 0.01 ***P < 0.001). (D) Voxelwise scatterplot comparison of tumour TSC values 
and mean diffusivity (MD) estimates shown for patient 5 at different timepoints. Horizontal and vertical red bar 
indicates the 50% percentile for the pre-treatment voxelwise MD and TSC estimates respectively. (E) Voxelwise 
scatterplot comparison of tumour mean diffusivity (MD) values and  Ktrans estimates shown for patient 5 at 
different timepoints. Horizontal and vertical red bar indicates the 50% percentile for the pre-treatment voxelwise 
MD and  Ktrans estimates respectively. Note the increase in the percentage of tumour voxels displaying ↑TSC and 
↑MD but ↓Ktrans at 6 months post-treatment. Spearman’s rho reported on scatterplots.
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mechanisms in response to radiotherapy, although slight differences in the timing of imaging following SRS 
may also be a factor. Membrane ion transporter failure, cellular apoptosis and swelling could all act to increase 
intracellular sodium content and restrict water diffusion whilst simultaneously within the same tumour there 
is loss of barriers to water diffusion and increased extracellular sodium secondary to necrosis and interstitial 
tumoural oedema. To better clarify changes in water and sodium distribution following SRS, further studies 
should be undertaken which incorporate both multi-compartment diffusion MRI  protocols49, and dedicated 
23Na-MRI acquisitions for direct estimation of the intracellular sodium  population50.
Following an early post-treatment rise in some tumours, we demonstrate that at 6 months post radiotherapy 
there is a marked decrease in the DCE-MRI derived microvascular parameters  vp,  Ktrans and  ve. Whilst there is a 
paucity of comparable studies in other histologically benign tumours, previous studies in cerebral metastases have 
demonstrated similar reductions in DCE-MRI derived microvascular parameters following SRS  treatment17,18. 
It has been proposed that the radiation sensitivity of tumours to dose fractions of 10 Gy or more is governed 
by the sensitivity of tumour endothelial cells to apoptosis and in the early post-irradiation period endothelial 
damage and increased capillary membrane permeability has been  reported51,52. Such an effect may underlie 
the early increases in  Ktrans,  ve and TSC seen in some  VS52. Conversely early increases in capillary membrane 
permeability and plasma extravasation may result in the observed early reduction in the measured ‘functional’ 
microvasculature in some tumours, as erythrocyte concentration and elevation of interstitial fluid pressure above 
the intravascular blood pressure leads to vascular stasis and vascular collapse in the smaller  vessels52.
In malignant tumours, both direct cellular DNA damage leading to cellular necrosis/apoptosis and indirect 
mechanisms such as vascular damage induced hypoxia are thought to contribute to tumour cell death and 
macroscopic  radioresponse52–54. Our demonstration that there are increases in TSC and MD and decreases in 
tumour vascularity at 6 months post-SRS, with a demonstrable cohort of voxels displaying low  ve/Ktrans/vp and 
high TSC/MD, suggest that similar mechanisms also occur in histologically benign tumours such as  VS11,12. At 
low diffusion gradient b-values (b < 200 s/mm2), such as those used within the DTI acquisition in this study, 
increased microvascular perfusion can be misinterpreted as diffusion effects, resulting in increases in scalar 
diffusion metrics such as mean  diffusivity55. Although it is possible that such effects may explain some of the 
observed increases in both MD and DCE-MRI derived microvascular parameters at 2 weeks post-treatment, 
given the generally low plasma volume fraction,  vp (< 10%) in these tumours and the very low number of voxels 
displaying increased  Ktrans/vp at 6 months post-treatment, it is unlikely that perfusion effects play a dominant 
role in explaining the increased post-treatment MD and TSC values observed. Further studies, however, that 
incorporate more advanced diffusion acquisitions, such as IVIM (intravoxel-incoherent motion) imaging, that 
allow specific assessment of the vascular contribution to the diffusion signal should be  undertaken56.
As a treatment modality radiotherapy preferentially targets proliferating tumour cell populations in the 
M and  G2 phase of the cell  cycle11,57, and within growing VS tumour associated macrophages (TAM) rather 
than Schwann cells were previously found to account for the majority of  Ki67+ proliferating  cells1,3,16. Along-
side Schwann cell death, apoptosis or necrosis of radiosensitive TAM populations may also contribute to the 
observed changes in TSC and MD  seen58. In previous studies an intimate link between tumour vascularity and 
infiltration of VEGF-expressing TAMs in VS has been demonstrated and our findings raise the interesting pos-
sibility that the observed growth attenuation seen in responsive tumours following SRS is also a manifestation 
of reduced tumoural vascular supply and decreased infiltration of pro-tumourigenic TAMs into the tumour 
 microenvironment1,3,16. Whilst the absence of resected tissue in SRS treated VS cohorts limits the ability to test 
these hypotheses directly future human imaging studies incorporating DCE-MRI and established PET tracers 
of inflammation in VS could be undertaken so that post-SRS changes in tumoural TAM density can be evalu-
ated in vivo1,3,16.
The present study is the first demonstration that early changes in the cellular viability, microstructure and 
microvasculature of SRS treated VS can be detected in vivo using clinically applicable MRI techniques. A limita-
tion of this pilot study, however, is that the number of study patients is low and a key question for future studies 
is the generalisability of the observed findings across the whole spectrum of VS undergoing radiotherapy. Within 
this study radiological follow-up of included patients was furthermore limited to only 6 months. Studies have 
shown that up to 63% of SRS treated patients can show transient tumour expansion or swelling after SRS and 
our volumetric tumour measurements support this, demonstrating a non-significant increase in VS volume at 
6 months post-treatment8,9. Pollock et al. showed that 57% of tumours with transient swelling demonstrated 
eventual tumour regression, with many authors recommending at least two years of radiological follow-up 
before declaring treatment a  failure8,9. Ultimately, the goal would be that these early imaging changes correlate 
to and predict the success or failure of radiotherapy. This will of course require future studies incorporating a 
larger population of VS and long-term imaging follow-up at 18 months and 3 years post-treatment to evaluate 
the ability of these early imaging biomarkers to predict later tumour response and differentiate true treatment 
failure from transient swelling.
Conclusions
Through a pilot, multinuclear MRI study we present the first in vivo study of temporal changes in the microstruc-
ture, microvasculature, and cellular physiology of VS undergoing SRS treatment. We demonstrate that changes 
in sodium homeostasis and the tumour microvasculature occur as early as 2 weeks post-treatment and that by 
6 months post-SRS there are demonstrable decreases in MRI markers of cellular density and the microvascula-
ture in treated VS. Our study provides new insights into the post-SRS VS microenvironment and future studies 
should investigate these MRI metrics as early biomarkers of SRS response.
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